Article · Wikipedia archive · Last revised Jul 19, 2026

Acotiamide

Acotiamide, sold under the brand names Acofide, and Dyspevict is a medication manufactured and approved in Japan and Russia for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia. It acts as an acetylcholinesterase inhibitor.

Last revised
Jul 19, 2026
Read time
≈ 1 min
Length
246 w
Citations
5
Source
Wikipedia ↗
Acotiamide
Clinical data
Trade namesAcofide, others
Other namesYM-443, Z-338
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • JP: Rx-only
Pharmacokinetic data
Protein binding84.21–85.95%
MetabolismUGT1A8 and 1A9 (major)
Elimination half-life10.9–21.7 hours
ExcretionFeces (92.7%), urine (5.3%)1
Identifiers
  • N-{2-[bis(1-Methylethyl)amino]ethyl}-2-{[(2-hydroxy-4,5-dimethoxyphenyl)carbonyl]amino}-1,3-thiazole-4-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H30N4O5S
Molar mass450.55 g·mol−1
3D model (JSmol)
  • O=C(Nc1nc(C(=O)NCCN(C(C)C)C(C)C)cs1)c2cc(OC)c(OC)cc2O
  • InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27) checkY
  • Key:TWHZNAUBXFZMCA-UHFFFAOYSA-N checkY
 X markNcheckY (what is this?)  (verify)

Acotiamide, sold under the brand names Acofide,23 and Dyspevict is a medication manufactured and approved in Japan and Russia4 for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.5 It acts as an acetylcholinesterase inhibitor.

References

References

  1. "Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.
  2. Nowlan ML, Scott LJ (August 2013). "Acotiamide: first global approval". Drugs. 73 (12): 1377–83. doi:10.1007/s40265-013-0100-9. PMID 23881665. S2CID 20383853.
  3. Matsunaga Y, Tanaka T, Saito Y, Kato H, Takei M (February 2014). "[Pharmacological and clinical profile of acotiamide hydrochloride hydrate (Acofide(®) Tablets 100 mg), a novel therapeutic agent for functional dyspepsia (FD)]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 143 (2): 84–94. doi:10.1254/fpj.143.84. PMID 24531902.
  4. "Dyspevict (acotiamide) Film-Coated Tablets. Full Prescribing Information". Russian State Register of Medicines (in Russian). Dr. Reddy's Laboratories. Retrieved 4 April 2025.
  5. Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H (June 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage". Neurogastroenterology and Motility. 22 (6): 618–e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698. S2CID 41298446.